8-K: Earth Science Tech Reclassifies as Pharmaceutical Entity

Earth Science Tech, Inc. formally directs financial data providers to update its industry classification to SIC 2834, reflecting its pharmaceutical operations since 2022.

Summary

• Earth Science Tech, Inc. (ETST) has issued a formal directive to financial data providers, news aggregators, and brokerage platforms to update its industry classification to SIC 2834 (Pharmaceutical Preparations).
• The company has been operating within the healthcare and pharmaceutical sectors since a strategic pivot initiated in 2022, moving away from legacy CBD or cannabis-related industries.
• The recent clearance of its 15c-211 was the final regulatory step in establishing ETST as a transparent, fully compliant pharmaceutical entity.
• ETST's operational pillars include pharmaceutical compounding through RxCompoundStore.com and Mister Meds, and telemedicine infrastructure via Peaks Curative and DOConsultations.
• The company is actively engaging with major data desks like Bloomberg, Morningstar, and S&P Global to ensure a permanent update to all financial websites.
• Subsidiaries include RxCompoundStore.com (licensed in 29 states/territories), Mister Meds (acquired Oct 2024, licensed March 2025, sterile compounding facility), Peaks Curative (telemedicine platform, expanded into veterinary market via Zoolzy.com), Las Villas Health Care (brick-and-mortar facility), DOConsultations (home therapies), Avenvi, LLC (real estate, manages $10 million share repurchase program), MagneChef (80% interest, direct-to-consumer retail), and Earth Science Foundation, Inc. (nonprofit).

Sentiment

Score: 7

Explanation: The formal reclassification and regulatory clearance are positive steps for market clarity and compliance, indicating a clear strategic direction. However, the necessity of issuing a directive to correct long-standing misclassification suggests a previous disconnect between the company's operations and public perception.

Positives

• Formal reclassification to SIC 2834 (Pharmaceutical Preparations) provides clarity on the company's current business focus.
• Clearance of 15c-211 signifies a final regulatory step in establishing ETST as a transparent, fully compliant pharmaceutical entity.
• The company has diversified operations across pharmaceutical compounding, telemedicine, and real estate development.
• Expansion of compounding pharmacy licenses (RxCompoundStore.com in 29 states/territories, Mister Meds pursuing additional states).
• Acquisition of Mister Meds (October 2024) and its subsequent full compounding licensure (March 2025) enhances compounding capabilities.
• Expansion into the veterinary market through the acquisition of Zoolzy.com by Peaks Curative.
• Ongoing $10 million share repurchase program managed by Avenvi, LLC.

Negatives

• The need for a formal directive indicates that market perception and data tagging have not accurately reflected the company's business for an extended period (since 2022).
• Legacy databases still erroneously tag ETST as a CBD firm, suggesting a potential lag in market understanding and investor awareness.

Risks

• Actual results may differ materially from forward-looking statements due to risks and uncertainties.
• Risks include those related to the markets for the company's products and services.
• Fluctuations in costs of goods and services and other expenses.
• Impact of government regulations.
• Potential litigations.
• General business conditions.

Future Outlook

The company is aggressively moving to ensure the market accurately perceives its pharmaceutical-focused identity. It aims to expand its telemedicine services nationwide through its healthcare provider network and ongoing licensure expansion for its pharmacies. MagneChef is in the process of expanding its product line for new offerings.

Management Comments

• "The recent clearance of our 15c-211 was the final regulatory step in establishing ETST as a transparent, fully compliant pharmaceutical entity."
• "Despite this milestone and our official SEC classification of SIC 2834 that has been in place since 2022, many legacy databases still erroneously tag ETST as a CBD firm. We are now aggressively moving to ensure the market sees the accurate, pharmaceutical-focused identity of our company."

Industry Context

This announcement reflects a broader trend of companies refining their business models and seeking accurate market representation, especially those transitioning from emerging or controversial sectors like cannabis to more established healthcare and pharmaceutical industries. The emphasis on regulatory compliance (15c-211 clearance) and formal SIC code alignment is crucial for attracting mainstream investors and financial institutions. The diversification into telemedicine and compounding pharmacies aligns with growing demand for personalized medicine and remote healthcare services.

Comparison to Industry Standards

• The company's focus on pharmaceutical compounding through RxCompoundStore.com and Mister Meds aligns with the specialized needs of the pharmaceutical industry, particularly for customized medications.
• The development of telemedicine infrastructure via Peaks Curative and DOConsultations positions ETST within the rapidly expanding digital health sector, comparable to platforms like Teladoc Health or Amwell, though ETST's focus is on clinical delivery of its own compounded products.
• The acquisition of Zoolzy.com for veterinary telemedicine indicates an expansion into a niche but growing segment of the healthcare market, similar to specialized veterinary telehealth providers.
• The company's efforts to ensure accurate SIC code classification (2834) are standard practice for publicly traded pharmaceutical entities to ensure proper industry benchmarking and investor perception, similar to how major pharmaceutical companies like Pfizer (PFE) or Eli Lilly (LLY) are classified.

Stakeholder Impact

• Shareholders: Increased clarity on the company's business model and industry classification may improve investor confidence and attract new investors who focus on the pharmaceutical sector. The $10 million share repurchase program could support share price.
• Financial Data Providers/Aggregators: Required to update their databases, ensuring accurate information dissemination.
• Customers (of RxCompoundStore, Mister Meds, Peaks Curative, etc.): Continued and potentially expanded access to specialized medications and telemedicine services.
• Employees: A clearer strategic direction and regulatory compliance can provide stability and focus.

Next Steps

• Engage with major data desks (Bloomberg, Morningstar, S&P Global) to ensure permanent updates to financial websites.
• Pursue licensure for RxCompoundStore.com in remaining U.S. states.
• Mister Meds is applying for licensure in states not yet serviced by RxCompound.
• Peaks Curative aims to offer services nationwide through its healthcare provider network and ongoing pharmacy licensure expansion.
• MagneChef is in the process of expanding its product line for new offerings.

Key Dates

Recommendation

The reclassification is a positive step for transparency and regulatory alignment, potentially attracting a new investor base. However, this filing primarily addresses market perception rather than immediate financial performance. While the strategic pivot to pharmaceuticals and telemedicine is clear, the financial impact and growth trajectory of these operations are not detailed. The share repurchase program is a positive signal, but without more comprehensive financial data, a "hold" position is prudent to observe the execution of the pharmaceutical strategy and its financial results.

Keywords

Pharmaceutical Preparations, Healthcare, Telemedicine, Compounding Pharmacy, SEC Classification, SIC 2834, ETST, Earth Science Tech, RxCompoundStore, Mister Meds, Peaks Curative, Avenvi, Real Estate Development, Share Repurchase